Indiana Trust & Investment Management CO reduced its position in shares of Eli Lilly And Co (NYSE:LLY) by 13.4% during the second quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 10,383 shares of the company’s stock after selling 1,604 shares during the quarter. Indiana Trust & Investment Management CO’s holdings in Eli Lilly And Co were worth $886,000 at the end of the most recent quarter.
Other hedge funds have also recently bought and sold shares of the company. Van ECK Associates Corp raised its stake in Eli Lilly And Co by 10.8% during the 1st quarter. Van ECK Associates Corp now owns 587,502 shares of the company’s stock worth $45,455,000 after buying an additional 57,487 shares during the period. OppenheimerFunds Inc. raised its stake in Eli Lilly And Co by 8.1% during the 4th quarter. OppenheimerFunds Inc. now owns 43,699 shares of the company’s stock worth $3,690,000 after buying an additional 3,257 shares during the period. MetLife Investment Advisors LLC acquired a new position in Eli Lilly And Co during the 4th quarter worth approximately $25,319,000. Tocqueville Asset Management L.P. raised its stake in Eli Lilly And Co by 15.5% during the 4th quarter. Tocqueville Asset Management L.P. now owns 26,095 shares of the company’s stock worth $2,204,000 after buying an additional 3,495 shares during the period. Finally, Thrivent Financial For Lutherans raised its stake in Eli Lilly And Co by 51.4% during the 4th quarter. Thrivent Financial For Lutherans now owns 139,846 shares of the company’s stock worth $11,812,000 after buying an additional 47,461 shares during the period. 76.03% of the stock is currently owned by institutional investors and hedge funds.
LLY has been the topic of a number of research reports. Jefferies Financial Group reaffirmed a “buy” rating and set a $91.00 price target on shares of Eli Lilly And Co in a research note on Friday, March 23rd. Zacks Investment Research raised Eli Lilly And Co from a “hold” rating to a “buy” rating and set a $86.00 price target on the stock in a research note on Monday, March 26th. BMO Capital Markets reaffirmed a “sell” rating and set a $74.00 price target on shares of Eli Lilly And Co in a research note on Wednesday, April 4th. HC Wainwright reissued a “buy” rating on shares of Eli Lilly And Co in a report on Wednesday, April 18th. Finally, Credit Suisse Group set a $80.00 price objective on Eli Lilly And Co and gave the stock a “hold” rating in a report on Sunday, April 22nd. Two analysts have rated the stock with a sell rating, nine have assigned a hold rating and eleven have given a buy rating to the company. The company has an average rating of “Hold” and a consensus target price of $93.67.
Eli Lilly And Co opened at $86.56 on Friday, Marketbeat.com reports. The company has a market capitalization of $93.90 billion, a PE ratio of 20.22, a price-to-earnings-growth ratio of 1.50 and a beta of 0.25. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.41 and a quick ratio of 1.01. Eli Lilly And Co has a 12-month low of $73.69 and a 12-month high of $89.09.
Eli Lilly And Co (NYSE:LLY) last released its earnings results on Tuesday, April 24th. The company reported $1.34 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.13 by $0.21. The company had revenue of $5.70 billion during the quarter, compared to analyst estimates of $5.51 billion. Eli Lilly And Co had a return on equity of 35.37% and a net margin of 4.82%. Eli Lilly And Co’s quarterly revenue was up 9.0% on a year-over-year basis. During the same period in the prior year, the company posted $0.98 earnings per share. analysts anticipate that Eli Lilly And Co will post 5.15 earnings per share for the current fiscal year.
The firm also recently announced a quarterly dividend, which will be paid on Monday, September 10th. Stockholders of record on Wednesday, August 15th will be issued a $0.5625 dividend. This represents a $2.25 annualized dividend and a dividend yield of 2.60%. The ex-dividend date is Tuesday, August 14th. Eli Lilly And Co’s dividend payout ratio is presently 52.57%.
In other news, major shareholder Lilly Endowment Inc sold 180,000 shares of the company’s stock in a transaction that occurred on Friday, June 15th. The stock was sold at an average price of $86.65, for a total value of $15,597,000.00. Following the completion of the transaction, the insider now directly owns 122,050,804 shares of the company’s stock, valued at $10,575,702,166.60. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, SVP Christi Shaw sold 8,426 shares of the company’s stock in a transaction that occurred on Tuesday, May 29th. The shares were sold at an average price of $82.10, for a total value of $691,774.60. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 987,464 shares of company stock valued at $82,748,955. 0.11% of the stock is currently owned by corporate insiders.
Eli Lilly And Co Company Profile
Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates through two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly And Co (NYSE:LLY).
Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.